Ergoteles LLC Cellectis S.A. Transaction History
Ergoteles LLC
- $68.2 Billion
- Q3 2023
Shares
1 transactions
Others Institutions Holding CLLS
# of Institutions
31Shares Held
9.83MCall Options Held
0Put Options Held
30.9K-
Long Focus Capital Management, LLC San Juan, PR4.49MShares$8.75 Million0.64% of portfolio
-
Capital International Investors Los Angeles, CA1.85MShares$3.61 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$2.8 Million0.0% of portfolio
-
Baillie Gifford & CO827KShares$1.61 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA425KShares$827,8390.0% of portfolio
About Cellectis S.A.
- Ticker CLLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,510,800
- Market Cap $88.7M
- Description
- Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...